Clinical Trial Results: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing biomarker-directed pembrolizumab-based combination therapy in advanced non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• MK-3475-495/KEYNOTE-495 combination therapy
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-06-08